PMID- 31012989 OWN - NLM STAT- MEDLINE DCOM- 20200312 LR - 20200312 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 123 Suppl 5 DP - 2019 May TI - Metformin may offer no protective effect in men undergoing external beam radiation therapy for prostate cancer. PG - 36-42 LID - 10.1111/bju.14709 [doi] AB - OBJECTIVES: To assess whether metformin reduces radio-resistance and increases survival in men undergoing external beam radiation therapy (EBRT) for prostate cancer (PCa), and to determine its effect on hypoxia inducible factor 1-alpha (HIF1alpha). PATIENTS AND METHODS: All patients treated with curative intent with EBRT for PCa at a major cancer centre between 2000 and 2007 were included in this study. The outcome measures of time to biochemical failure (BF), metastasis, PCa-specific mortality and overall survival (OS) were analysed in those taking metformin vs those not, using competing risk and Cox regression models. To determine metformin's effect on HIF1alpha expression and survival in vitro, PC3 cells with high basal HIF1alpha levels were subjected to increasing doses of metformin after H(2) O(2) -induced oxidative stress. RESULTS: A total of 2055 eligible cases, including 113 who were on metformin, were identified, with a median follow-up of 95.7 months. There were no differences in age, initial prostate-specific antigen level, Gleason score, T-stage, D'Amico risk class or duration of androgen deprivation therapy (ADT) between patients who were or were not on metformin. Treatment with metformin did not result in any apparent improvement in time to BF, time to metastasis detection or OS, but there was a 1.5-fold increase in PCa-specific deaths (P = 0.045) in patients on metformin and ADT when adjusted for cancer risk and comorbidities. When comparing patients on high-dose metformin (>1 g/d) with those on low-dose metformin (